阿布昔替尼成功治疗难治性结节性痒疹。
Successful treatment of refractory prurigo nodularis with abrocitinib.
作者信息
Sun Fang, Wu Zhenzhen
机构信息
Derpartment of Dermatology Affiliated AoYang Hospital of Jiangsu University Zhangjiagang Jiangsu China.
出版信息
Clin Case Rep. 2024 Mar 7;12(3):e8606. doi: 10.1002/ccr3.8606. eCollection 2024 Mar.
Abstract
Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK-STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a conclusion that abrocitinib as an inhibitor of Jak is a promising choice for the treatment of prurigo nodularis.
摘要
结节性痒疹通常难以通过传统疗法进行治疗。鉴于其发病机制和难治性，我们展示了一个病例，其中抑制JAK-STAT信号传导可能显著改善结节性痒疹。基于这些结果，我们得出结论，阿布昔替尼作为一种Jak抑制剂是治疗结节性痒疹的一个有前景的选择。
Zotero 插件